Compare Novartis AG (NVS) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Financial Select Sector SPDR Fund — how do they compare? Novartis AG trades at $137.69 (market cap $262.64B), while Financial Select Sector SPDR Fund trades at $57.29. The key difference: Novartis AG pays a 3.44% dividend while Financial Select Sector SPDR Fund pays none, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | XLF | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | — |
52-Week High | $168.62 | $58.55 |
52-Week Low | $121.80 | $47.80 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
XLF, the Financial Select Sector SPDR Fund, trades at $57.3, down 1.38% over 24 hours. The technical outlook is neutral overall, with bullish moving averages but neutral oscillators, and key support at $57. Recent news highlights consolidation amid shifting interest rate expectations and fund manager rotation into financials in Q2 2026. The ETF offers exposure to 76 large-cap U.S. financial firms with a low expense ratio of 0.08%.
The outlook for XLF is balanced. Potential upside exists from rising interest rates benefiting banks and institutional inflows, but risks include economic sensitivity and sector volatility. The neutral technical and sentiment signals suggest a wait-and-see approach, with the dividend providing modest income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
